(Q36588861)

15 August 2017

1 reference

title

Use of biologics in rheumatoid arthritis: where are we going? (English)

1 reference

15 August 2017

0 references

Frank Pucino

1

1 reference

15 August 2017

Phyllis Tish Harbus

series ordinal

2

1 reference

15 August 2017

Raphaela Goldbach-Mansky

series ordinal

3

1 reference

15 August 2017

publication date

1 September 2006

1 reference

American Journal of Health-System Pharmacy

15 August 2017

published in

1 reference

15 August 2017

volume

63

1 reference

15 August 2017

issue

18 Suppl 4

1 reference

15 August 2017

page(s)

S19-41

1 reference

Biologic therapies in clinical development for the treatment of rheumatoid arthritis

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Emerging biologic drugs for the treatment of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Beyond methotrexate: biologic therapy in rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

T-cell-activation inhibitors in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Treatment of rheumatoid arthritis: new therapeutic approaches with biological agents.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Biologic therapies in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Development of anti-TNF therapy for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Infliximab treatment maintains employability in patients with early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Cardiovascular death in rheumatoid arthritis: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Long term safety of infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Safety of tumour necrosis factor-alpha antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Listeria meningitis associated with infliximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Listeria meningitis after treatment with infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

[Infliximab therapy in Crohn's disease complicated by Listeria monocytogenes meningoencephalitis]

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Infliximab treatment and pregnancy outcome in active Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Adalimumab use in pregnancy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Interpretation of cost-effectiveness analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Regional differences in Finland in the prevalence of rheumatoid factor in the presence and absence of arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Anakinra: a review of its use in the management of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Durability and rapidity of response to anakinra in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Rapid responses to anakinra in patients with refractory adult-onset Still's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Refractory adult onset Still's disease successfully treated with anakinra

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Genetic origin of lupus in NZB/SWR hybrids: lessons from an intercross study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Capability for daily activities in old people with rheumatoid arthritis: a population based study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Chemokines and their receptors in rheumatoid arthritis: future targets?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

An APRIL to remember: novel TNF ligands as therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Interleukin-10 therapy--review of a new approach

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

T cell epitope-specific immune therapy for rheumatic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Control of rheumatoid arthritis by oral tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

Gene transfer to human joints: progress toward a gene therapy of arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060365

31 March 2020

Identifiers

DOI

10.2146/AJHP060365

1 reference

15 August 2017

1 reference